SavedAdd your journal

Journals / Kocatepe Tıp Dergisi / 2026 / Cilt: 27 Sayı: 1

THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA

ENDOMETRİYAL KANSERDE IDH1- R132H MUTASYONUNUN EKSPRESYONU VE PROGNOSTİK ÖNEMİ

Hacer Demir(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0003-1235-9363
Çiğdem Özdemir(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, PATOLOJİ ANABİLİM DALI)0000-0001-8500-0744
Meltem Baykara(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0003-3291-8134
Ayşe Demirci(Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği)0000-0002-6291-7573
İsmail Beypınar(Eskişehir Şehir Hastanesi,Tıbbi Onkoloji Kliniği)0000-0002-0853-4096
Sena Ece Davarcı(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0003-1142-9411
Cem Yağmur Özdemir(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, KADIN HASTALIKLARI VE DOĞUM ANABİLİM DALI, JİNEKOLOJİK ONKOLOJİ CERRAHİSİ BİLİM DALI)0000-0001-5560-2162
Yaşar Culha(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, TIBBİ ONKOLOJİ BİLİM DALI)0000-0002-0317-7552
Dağıstan Tolga Arıöz(AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, KADIN HASTALIKLARI VE DOĞUM ANABİLİM DALI, JİNEKOLOJİK ONKOLOJİ CERRAHİSİ BİLİM DALI)0000-0003-3616-0789
Pages
1–9
Publication Date
2026-01-12
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The primary endpoints were defined as overall survival (OS) and event-free survival (EFS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Isocitrate dehydrogenases (IDHs) are rate-limiting enzymes in the intracellular tricarboxylic acid (TCA) cycle.
📊
Key Findings & Data:IDH1/2 mutation may have an oncogenic effect and has also enabled the discovery of new therapeutic approaches for treating changes caused by this mutation.
💡
Conclusion & Impact:The primary endpoints were defined as overall survival (OS) and event-free survival (EFS).
🔬Design:Review & Systematic Survey
📍Scope:2012 Verileri
⚙️Variables:Endometriyum kanseri · İzositrat dehidrogenazlar · Prognoz.

Abstract

OBJECTIVE: Isocitrate dehydrogenases (IDHs) are rate-limiting enzymes in the intracellular tricarboxylic acid (TCA) cycle. IDH1/2 mutation may have an oncogenic effect and has also enabled the discovery of new therapeutic approaches for treating changes caused by this mutation. Genetic alterations and changes in DNA methylation are known to contribute to the pathogenesis of endometrial cancer. Still, there is no information yet about a relationship between IDH 1 mutation and endometrial cancer. In this study, aimed to evaluate the frequency of IDH1 mutations in endometrial cancer and its effect on prognosis. MATERIAL AND METHODS: For this study, we reviewed the files of 150 patients diagnosed with endometrial cancer who were treated and monitored between January 2012 and December 2020. 104 patients had adequate tumor tissue available in the pathology laboratory. The IDH-R132H mutation was assessed using immunohistochemistry. The primary endpoints were defined as overall survival (OS) and event-free survival (EFS). RESULTS: The study included 104 patients diagnosed with endometrial cancer. The patients expressing mutant IDH had a significantly higher rate of stage 4 disease (p=0.008), distant metastasis (p=0.034), and recurrence (p=0.037). The 3-year and 5-year event-free survival rates were significantly shorter in this group, with a p-value of 0.044. CONCLUSIONS: This is the first study showing that the IDH1-R132H mutation can be detected in patients with endometrial cancer. Our findings indicate that this mutation is a poor prognostic factor for these patients. We believe that the results of our study will form the basis of treatment studies targeting this mutation in endometrial cancer patients with the IDH1-R132H mutation.

Özet

AMAÇ: İzositrat dehidrogenazlar (IDH'ler), hücre içi trikarboksilik asit (TCA) döngüsünde yer alan hız sınırlayıcı enzimlerdir. IDH1/2 mutasyonu onkojenik etkiye sahip olabilir ve ayrıca bu mutasyonun neden olduğu değişikliklerin tedavisi için yeni terapötik yaklaşımların keşfedilmesini sağlamıştır. Çeşitli genetik değişikliklerin ve DNA metilasyon değişikliklerinin endometrial kanserin patogenezinden sorumlu olabileceği bilinmektedir, ancak IDH 1 mutasyonu ile endometrial kanser arasındaki ilişki hakkında henüz bilgi yoktur. Bu çalışmada, endometrium kanserinde IDH1 mutasyonunun sıklığını ve prognoz üzerindeki etkisini değerlendirmeyi amaçladık. GEREÇ VE YÖNTEM: Çalışma için 01.01.2012 ile 30.12.2020 tarihleri arasında endometrial kanser tanısıyla tedavi edilen ve takip edilen 150 hastanın dosyaları tarandı ve patoloji laboratuvarında yeterli tümör dokusuna ulaşılabilen 104 hasta çalışmaya dahil edildi. IDH-R132H mutasyonu immünohistokimyasal olarak değerlendirildi. Genel sağ kalım (OS) ve olay içermeyen sağ kalım (EFS) birincil son noktalar olarak tanımlandı. BULGULAR: Çalışmaya endometrial kanser tanısı almış toplam 104 hasta dahil edildi. Mutant IDH ifade eden hastalarda evre 4 hastalık (p=0,008), uzak metastaz (p=0,034) ve tekrarlama (p=0,037) oranı anlamlı derecede daha yüksekti. Ayrıca, 3 ve 5 yıllık olay içermeyen sağ kalım bu grupta anlamlı derecede daha kısaydı (p=0,044). SONUÇ: Bu, IDH1-R132H mutasyonunun endometrial kanserli hastalarda tespit edilebileceğini gösteren literatürdeki ilk çalışmadır ve sonuçlarımız IDH1-R132H mutasyonunun varlığının bu hastalarda zayıf bir prognostik faktör olduğunu düşündürmektedir. Çalışmamızın sonuçlarının IDH1-R132H mutasyonu olan endometrial kanserli hastalarda bu mutasyonu hedef alan tedavi çalışmalarının temelini oluşturacağına inanıyoruz.

🔖

Cite This Article

Demir, H., Özdemir, Ç., Baykara, M., Demirci, A., Beypınar, İ., Davarcı, S. E., Özdemir, C. Y., Culha, Y., Arıöz, D. T. (2026). THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA. Kocatepe Tıp Dergisi, Cilt: 27 Sayı: 1, 1–9. https://doi.org/10.18229/kocatepetip.1576255

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (41)

  1. Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA. Cancer J. Clin. 2020;70:145–64.
  2. Amant F, Mirza MR, Koskas M, et al. C. L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. Off. organ Int. Fed. Gynaecol. Obstet. 2018;143:37–50.
  3. Wartko P, Sherman ME, Yang HP, et al. Recent changes in endometrial cancer trends among menopausal- age U.S. women. Cancer Epidemiol. 2013;37:374–7.
  4. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet. Oncol. 2014;15:e268-78.
  5. Kandoth C, Schultz N, Cherniak AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
  6. Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of Endometrial Cancers. Obstet. Gynecol. Int. 2010;4(8):984013.
  7. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
  8. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3:730–41.
  9. Reitman, ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010;102:932–41.
  10. Lee SM, Koh H, Park DC, et al. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 2002;32:1185–96.
  11. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.
  12. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012:483:474–8.
  13. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer. 2009;125:353–5.
  14. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro. Oncol. 2016;18:16–26.
  15. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225– 34.
  16. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate- dependent dioxygenases. Cancer Cell. 2011;19:17–30.
  17. Joberty G, Boesche M, Brown JA, et al. Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. ACS Chem. Biol. 2016;11(7):2002-10.
  18. Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12:463–9.
  19. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain- containing proteins. Nature. 2006;439:811–6.
  20. Kohli RM, Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472-9.
  21. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12.
  22. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009;360:765–73.
  23. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010;28:3636–43.
  24. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumors. J. Pathol. 2011;224:334–43.
  25. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72–9.
  26. Ghiam AF, Cairns RA, Thoms J, et al. IDH mutation status in prostate cancer. Oncogene. 2011;31:3826.
  27. Liu X, Kato Y, Kaneko MK, et al. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med. 2013;2:803–14.
  28. Pietrak B, Zhao H, Qi H, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. Biochemistry. 2011;50:4804–12.
  29. DiNardo CD. Ivosidenib in IDH1-Mutated acute myeloid leukemia. N. Engl. J. Med. 2018;379:1186.
  30. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomized, double-blind, placebo-controlled, phase 3 study. Lancet. Oncol. 2020;21:796–807.
  31. Pennanen M, Tynninen O, Kytöla S, et al. IDH1 Expression via the R132H Mutation-Specific Antibody in Adrenocortical Neoplasias-Prognostic Impact in Carcinomas. J. Endocr. Soc. 2020;4(4):1-10.
  32. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245–54.
  33. Shvartsbeyn M, Yee H, Chiriboga L, et al. IDH-1R132 H Mutation- and p53 Mutation-Rich Endometrial and Ovarian Serous Adenocarcinomas: A Tissue Microarray Study. Am. J. Clin. Pathol. 2012;138:A094.
  34. Alexa M, Hasenburg A, Battista, MJ. The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers (Basel). 2021;13(6):1478.
  35. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123, 802–13.
  36. Birner P, Toumangelova-Uzeir K, Natchev S, et al. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol. 2011;49:88–93.
  37. Khan I, Waqas M, Shamim MS. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. J Pak Med Assoc. 2017;67(5):816–7.
  38. Van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-50.
  39. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012;120:4649–52.
  40. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcomes in acute myeloid leukemia. Blood. 2013;121:4917-24.
  41. Borger D, Goyal L, Yau T, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 2014;20:1884–90.